Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials-Reference-Cited by-同舟云学术

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

Published:2020-12 Issue:12 Volume:21 Page:1620-1629
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

André Thierry,Meyerhardt Jeffrey,Iveson Timothy,Sobrero Alberto,Yoshino Takayuki,Souglakos Ioannis,Grothey Axel,Niedzwiecki Donna,Saunders Mark,Labianca Roberto,Yamanaka Takeharu,Boukovinas Ioannis,Vernerey Dewi,Meyers Jeffrey,Harkin Andrea,Torri Valter,Oki Eiji,Georgoulias Vassilis,Taieb Julien,Shields Anthony,Shi Qian

Funder

National Cancer Institute

National Institute for Health Research

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma;Moertel;N Engl J Med,1990

2. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089;Haller;J Clin Oncol,2005

3. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials;Sargent;J Clin Oncol,2005

4. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;Andre;N Engl J Med,2004

5. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer;Haller;J Clin Oncol,2011

Cited by 178 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis;Journal of Clinical Oncology;2024-09-04

2. Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months;European Journal of Cancer;2024-09

3. Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review;Cancer Treatment Reviews;2024-09

4. PRM1201 effectively inhibits colorectal cancer metastasis via shaping gut microbiota and short- chain fatty acids;Phytomedicine;2024-09

5. Essential updates 2022–2023: Surgical and adjuvant therapies for locally advanced colorectal cancer;Annals of Gastroenterological Surgery;2024-08-19